AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 OCT 10 - (NewsRx.com & NewsRx.net) -- Early findings from a randomized trial investigating the effectiveness of tamoxifen to prevent breast cancer are reported in the Lancet.
Although tamoxifen reduced breast cancer incidence by a third compared with women given placebo, the authors of the study caution that it is still too early to fully assess the risk-to-benefit ratio of tamoxifen as a preventative strategy for breast cancer.
Tamoxifen is well-known in its effect to decrease recurrence of (and death from) breast cancer; however, three clinical trials on the use of tamoxifen to prevent breast cancer have reported mixed results. The overall evidence supports a reduction in the risk of breast cancer, but whether this benefit outweighs the risks and side effects associated with tamoxifen is unclear.
Jack Cuzick from Cancer Research U.K., lead investigator of the International Breast Cancer Intervention Study (IBIS-I) and colleagues undertook a double-blind placebo-controlled randomized trial of tamoxifen, 20 mg/day for 5 years, in around 7000 women from the U.K., Europe, Australia and New Zealand who were aged 35-70 years and who were at an increased risk of breast cancer (e.g., they had a family history of the disease or had a benign lesion associated with an increased risk of breast cancer).
The frequency of breast cancer was reduced by a third among women given tamoxifen (69 breast cancers in 3578 women in the tamoxifen group and 101 breast cancers in 3566 in the placebo group). Endometrial cancer - considered to be increased by tamoxifen use - was doubled in the tamoxifen group (11 instances compared with 5 in the control group), but this increase was not statistically significant, and all cases were localized (stage I) and curable ...